Pharmaceutical companies strive to prioritize patient-centered operations and processes, yet many fall short in effectively engaging patients in their programs.
Patient engagement programs are crucial for the treatment of diseases, providing a patient-centered approach that can lead to improved quality and safety outcomes. However, enrolling enough patients into these programs remains a key challenge.
The biggest challenge facing these programs is the low level of patient participation. Due to a lack of patient referrals, many are missing out on additional healthcare support, potentially negatively impacting health outcomes.
The root causes of low participation in patient engagement programs include regulatory constraints and a lack of understanding on the part of pharma companies. Sales teams face limitations on what they can discuss with healthcare providers, and calls about support programs are often not included in sales performance metrics, creating little incentive for sales representatives to actively promote them.
To improve patient uptake of these programs, both pharma companies and healthcare providers must have a better understanding of patient needs to effectively communicate the value of engagement programs and encourage patient enrollment.
Pharmaceutical companies should re-evaluate their approach to marketing patient engagement programs to healthcare providers. This includes providing training for sales teams to better understand and promote the programs, incorporating patient support programs into training events, and committing to a more holistic approach to treatment.
Companies may also need to re-evaluate their investment in patient engagement programs and consider launch excellence strategies to ensure that resources are used effectively.
In a piece with the Medicine Maker, Ian Riches, Global Vice President of Patient Solutions and Head of Patient Solutions Europe at Ashfield Engage, an Inizio company explains how to overcome barriers to patient engagement in pharma programs.
Read more: https://themedicinemaker.com/business-regulation/staying-engaged
Jump to a slide with the slide dots.
From LED walls to real-time in-booth optimization, ASCO® 2025 uncovered how we should engage and evolve the congress experience.
Read moreIt’s been a few weeks since ASCO® 2025, but one moment from the podium still echoes in my mind - the possibility of curing metastatic cancer.
Read moreWith new therapies and personalized treatments helping patients live longer, the definition of success in oncology is evolving. Read more.
Read more